H+, K(+)-
ATPase inhibitors such as
omeprazole are the antisecretory agents of choice for the management of gastric acid hypersecretory states, including the
Zollinger-Ellison syndrome. However, long-term follow-up data on the overall efficacy and safety of these agents in large numbers of patients are lacking. In the current study we examined the long-term efficacy and safety of
omeprazole in 116 patients with
Zollinger-Ellison syndrome treated with oral
omeprazole at a single centre for up to 114 months (mean +/- S.E.M. = 38 +/- 3 months). The initial
omeprazole maintenance dose was established according to the acute upward dose titration method in 89/116 patients (77%). Gastric acid output was effectively controlled using 60 mg of
omeprazole once daily in 41/89 patients (46%) and 22/89 patients (25%) required twice daily
omeprazole therapy. The mean
ranitidine equivalent dose for patients who required 60 mg
omeprazole once daily (2.5 +/- 0.2 g/day) was significantly lower than the mean
ranitidine equivalent dose for patients who required more than 60 mg
omeprazole once daily (4.3 +/- 0.3 g/day). Long-term
omeprazole maintenance
therapy was discontinued in 36/116 patients (31%) but in no cases was discontinuation due either to
drug-induced side-effects or uncontrolled gastric acid output. Fasting serum
gastrin levels were significantly elevated above pre-treatment levels at only one time point during follow-up and were likely due to tumour growth rather than a
drug effect. The final long-term
omeprazole maintenance doses were lower than the initial doses but correlated closely with the pre-
omeprazole basal
acid output (r = 0.41, P < 0.001) and
ranitidine equivalent dose requirements (r = 0.49, P < 0.001). We conclude that
omeprazole effectively and safely controls gastric acid hypersecretion in all patients with
Zollinger-Ellison syndrome for up to nine years without evidence by tachyphylaxis.